See more : Humansoft Holding Company K.S.C.P. (HUMANSOFT.KW) Income Statement Analysis – Financial Results
Complete financial analysis of Teligent, Inc. (TLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teligent, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Oaktree Capital Group, LLC (OAK-PB) Income Statement Analysis – Financial Results
- Gunze Limited (3002.T) Income Statement Analysis – Financial Results
- Avicanna Inc. (AVCNF) Income Statement Analysis – Financial Results
- Compass Group PLC (CMPGF) Income Statement Analysis – Financial Results
- TC Energy Corporation (TNCAF) Income Statement Analysis – Financial Results
Teligent, Inc. (TLGT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.teligent.com
About Teligent, Inc.
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.
| Metric | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.31M | 65.90M | 67.25M | 66.88M | 44.25M | 33.74M | 18.22M | 8.56M | 7.81M | 6.09M | 3.78M | 4.07M | 4.58M | 2.62M | 2.87M | 3.56M | 3.56M | 4.36M | 15.90M | 19.25M | 34.59M | 33.20M | 34.20M | 35.10M | 31.20M | 28.90M | 28.00M | 24.40M | 22.00M | 20.10M | 18.30M | 16.00M | 15.70M | 18.40M | 17.80M |
| Cost of Revenue | 0.00 | 42.37M | 39.88M | 32.19M | 22.94M | 16.95M | 12.08M | 5.79M | 5.55M | 4.99M | 3.53M | 2.85M | 2.48M | 1.39M | 1.92M | 1.25M | 1.35M | 1.38M | 8.77M | 9.19M | 16.46M | 16.00M | 16.80M | 15.10M | 14.60M | 13.10M | 12.20M | 10.20M | 9.70M | 8.70M | 8.00M | 7.00M | 6.80M | 7.90M | 8.50M |
| Gross Profit | 45.31M | 23.52M | 27.37M | 34.69M | 21.32M | 16.79M | 6.15M | 2.78M | 2.26M | 1.11M | 251.00K | 1.22M | 2.11M | 1.23M | 947.00K | 2.31M | 2.21M | 2.99M | 7.13M | 10.06M | 18.14M | 17.20M | 17.40M | 20.00M | 16.60M | 15.80M | 15.80M | 14.20M | 12.30M | 11.40M | 10.30M | 9.00M | 8.90M | 10.50M | 9.30M |
| Gross Profit Ratio | 100.00% | 35.70% | 40.70% | 51.86% | 48.17% | 49.77% | 33.72% | 32.42% | 28.95% | 18.13% | 6.64% | 29.93% | 45.95% | 47.02% | 33.03% | 64.78% | 62.19% | 68.42% | 44.85% | 52.24% | 52.43% | 51.81% | 50.88% | 56.98% | 53.21% | 54.67% | 56.43% | 58.20% | 55.91% | 56.72% | 56.28% | 56.25% | 56.69% | 57.07% | 52.25% |
| Research & Development | 548.00K | 10.76M | 19.27M | 17.14M | 13.17M | 6.91M | 2.74M | 2.83M | 2.15M | 1.51M | 740.00K | 502.00K | 481.00K | 1.07M | 949.00K | 1.73M | 762.00K | 549.00K | 536.00K | 853.00K | 1.42M | 1.40M | 1.70M | 2.00M | 1.30M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 7.99M | 14.06M | 15.70M | 15.00M | 15.00M | 11.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 7.99M | 14.06M | 15.70M | 15.00M | 15.00M | 11.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 20.79M | 19.90M | 15.01M | 11.34M | 5.98M | 3.48M | 3.08M | 3.08M | 3.23M | 3.60M | 2.78M | 2.43M | 2.11M | 1.68M | 1.80M | 2.42M | 2.36M | 1.42M | 1.37M | 1.15M | 1.00M | 1.00M | 1.00M | 800.00K | 11.50M | 12.50M | 13.80M | 11.70M | 10.40M | 9.60M | 8.10M | 7.50M | 7.90M | 8.40M |
| Operating Expenses | 548.00K | 31.54M | 39.17M | 32.15M | 24.51M | 12.89M | 6.23M | 5.91M | 5.23M | 4.74M | 4.34M | 3.28M | 2.91M | 3.17M | 2.63M | 3.53M | 3.18M | 2.91M | 7.29M | 10.22M | 16.63M | 18.10M | 17.70M | 18.00M | 14.00M | 12.30M | 12.50M | 13.80M | 11.70M | 10.40M | 9.60M | 8.10M | 7.50M | 7.90M | 8.40M |
| Cost & Expenses | 548.00K | 73.92M | 79.05M | 64.34M | 47.44M | 29.83M | 18.31M | 11.70M | 10.78M | 9.73M | 7.87M | 6.13M | 5.39M | 4.56M | 4.55M | 4.78M | 4.53M | 4.29M | 16.06M | 19.41M | 33.09M | 34.10M | 34.50M | 33.10M | 28.60M | 25.40M | 24.70M | 24.00M | 21.40M | 19.10M | 17.60M | 15.10M | 14.30M | 15.80M | 16.90M |
| Interest Income | 0.00 | -21.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -962.00K | 17.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 281.00K | 13.00K | 938.00K | 0.00 | 48.00K | 129.00K | 4.00K | 0.00 | 0.00 | 283.00K | 2.13M | 2.75M | 0.00 | 3.40M | 0.00 | 2.00M | 1.30M | 1.00M | 600.00K | 700.00K | 600.00K | 800.00K | 700.00K | 500.00K | 0.00 | 800.00K | 1.00M |
| Depreciation & Amortization | 6.55M | 6.70M | 4.64M | 3.78M | 1.17M | 515.00K | 475.00K | 457.00K | 419.00K | 376.00K | 348.00K | 349.00K | 336.00K | 371.00K | 300.00K | 271.00K | 269.00K | 581.00K | 1.03M | 1.37M | 1.15M | 1.00M | 1.00M | 1.00M | 800.00K | 800.00K | 1.00M | 1.10M | 900.00K | 700.00K | 700.00K | 600.00K | 600.00K | 700.00K | 900.00K |
| EBITDA | 48.60M | -18.34M | -9.02M | -7.92M | 7.88M | 5.94M | 194.00K | -3.64M | -2.53M | -3.25M | -3.74M | -1.70M | -401.00K | -1.63M | -1.27M | -911.00K | -261.00K | 9.97M | 1.15M | -10.22M | -1.04M | 100.00K | -1.10M | 3.00M | 200.00K | 2.70M | -1.60M | 1.80M | 1.60M | 1.70M | 1.40M | 1.40M | 2.10M | 2.90M | 1.10M |
| EBITDA Ratio | 107.27% | -27.83% | -13.42% | -11.84% | 17.80% | 17.60% | 1.06% | -42.52% | -32.45% | -53.35% | -99.05% | -41.75% | -8.75% | -62.02% | -44.40% | -25.60% | -7.34% | 228.55% | 7.22% | -53.10% | -2.99% | 0.30% | -3.22% | 8.55% | 0.64% | 9.34% | -5.71% | 7.38% | 7.27% | 8.46% | 7.65% | 8.75% | 13.38% | 15.76% | 6.18% |
| Operating Income | 44.76M | -8.02M | -11.80M | 2.54M | -3.19M | 3.91M | -82.00K | -3.14M | -2.97M | -3.63M | -4.09M | -2.06M | -806.00K | -1.94M | -1.68M | -1.22M | -972.00K | 79.00K | -161.00K | -157.00K | 1.51M | -900.00K | -300.00K | 2.00M | 2.60M | 3.50M | 3.30M | 400.00K | 600.00K | 1.00M | 700.00K | 900.00K | 1.40M | 2.60M | 900.00K |
| Operating Income Ratio | 98.79% | -12.17% | -17.54% | 3.80% | -7.21% | 11.58% | -0.45% | -36.62% | -38.03% | -59.58% | -108.28% | -50.65% | -17.59% | -73.97% | -58.60% | -34.29% | -27.33% | 1.81% | -1.01% | -0.82% | 4.35% | -2.71% | -0.88% | 5.70% | 8.33% | 12.11% | 11.79% | 1.64% | 2.73% | 4.98% | 3.83% | 5.63% | 8.92% | 14.13% | 5.06% |
| Total Other Income/Expenses | 548.00K | -17.01M | -3.48M | -14.24M | 9.90M | 1.52M | -199.00K | -975.00K | -264.00K | -9.00K | -937.00K | 13.00K | 16.00K | -129.00K | 103.00K | 38.00K | 7.00K | -225.00K | -2.13M | -2.75M | -4.08M | -3.40M | -1.80M | 0.00 | -500.00K | -900.00K | -600.00K | 200.00K | 0.00 | -1.10M | 0.00 | 0.00 | 100.00K | -1.00M | -1.00M |
| Income Before Tax | 45.31M | -25.03M | -15.28M | -11.70M | 6.70M | 5.42M | -281.00K | -4.11M | -3.23M | -3.64M | -5.03M | -2.05M | -790.00K | -2.07M | -1.58M | -1.18M | -965.00K | -146.00K | -2.29M | -2.91M | -2.57M | -4.30M | -2.10M | 0.00 | 2.10M | 2.60M | 2.70M | 600.00K | 0.00 | -100.00K | 0.00 | 0.00 | 1.50M | 1.60M | -100.00K |
| Income Before Tax Ratio | 100.00% | -37.99% | -22.71% | -17.49% | 15.15% | 16.08% | -1.54% | -48.01% | -41.42% | -59.73% | -133.09% | -50.33% | -17.25% | -78.89% | -55.01% | -33.22% | -27.13% | -3.35% | -14.43% | -15.12% | -7.43% | -12.95% | -6.14% | 0.00% | 6.73% | 9.00% | 9.64% | 2.46% | 0.00% | -0.50% | 0.00% | 0.00% | 9.55% | 8.70% | -0.56% |
| Income Tax Expense | 45.31M | 91.00K | -85.00K | 287.00K | 35.00K | 173.00K | -197.00K | -184.00K | -226.00K | -217.00K | -108.00K | -196.00K | -453.00K | -458.00K | -279.00K | -290.00K | -208.00K | 330.00K | -271.00K | 5.86M | -601.00K | -1.30M | -600.00K | -100.00K | 600.00K | 600.00K | 900.00K | -100.00K | 600.00K | -200.00K | 0.00 | 500.00K | 700.00K | 1.00M | 500.00K |
| Net Income | 0.00 | -25.12M | -15.19M | -11.99M | 6.67M | 5.25M | -84.00K | -3.93M | -3.01M | -3.42M | -4.92M | -1.85M | -332.00K | -1.67M | -1.30M | -892.00K | -322.00K | 8.78M | -1.74M | -20.21M | -1.58M | -3.00M | -1.50M | 100.00K | -2.50M | 300.00K | -4.10M | 100.00K | 100.00K | 100.00K | 0.00 | 300.00K | 800.00K | 400.00K | -1.30M |
| Net Income Ratio | 0.00% | -38.13% | -22.59% | -17.92% | 15.07% | 15.56% | -0.46% | -45.86% | -38.52% | -56.17% | -130.23% | -45.51% | -7.25% | -63.63% | -45.27% | -25.07% | -9.05% | 201.19% | -10.94% | -104.99% | -4.58% | -9.04% | -4.39% | 0.28% | -8.01% | 1.04% | -14.64% | 0.41% | 0.45% | 0.50% | 0.00% | 1.88% | 5.10% | 2.17% | -7.30% |
| EPS | 0.00 | -4.67 | -2.85 | -2.26 | 1.26 | 1.05 | -0.02 | -0.99 | -0.76 | -2.30 | -3.31 | -1.24 | -0.23 | -1.30 | -1.08 | -0.77 | -0.28 | 7.68 | -1.59 | -19.81 | -1.65 | -3.17 | -1.59 | 0.10 | -2.57 | 0.30 | -4.90 | 0.10 | 0.10 | 0.20 | 0.00 | 0.30 | 1.00 | 0.60 | -1.80 |
| EPS Diluted | 0.00 | -4.67 | -2.85 | -2.26 | 0.99 | 0.82 | -0.02 | -0.99 | -0.76 | -2.30 | -3.31 | -1.24 | -0.23 | -1.30 | -1.08 | -0.74 | -0.28 | 7.68 | -1.59 | -19.81 | -1.58 | -3.17 | -1.59 | 0.10 | -2.50 | 0.30 | -4.60 | 0.10 | 0.10 | 0.20 | 0.00 | 0.30 | 1.00 | 0.60 | -1.80 |
| Weighted Avg Shares Out | 77.14M | 5.38M | 5.33M | 5.31M | 5.29M | 4.98M | 3.98M | 3.98M | 3.94M | 1.49M | 1.49M | 1.49M | 1.43M | 1.28M | 1.20M | 1.15M | 1.14M | 1.14M | 1.10M | 1.02M | 960.48K | 947.04K | 945.79K | 1.00M | 972.52K | 1.00M | 836.74K | 1.00M | 1.00M | 500.00K | 666.67K | 1.00M | 800.00K | 666.67K | 722.22K |
| Weighted Avg Shares Out (Dil) | 77.14M | 5.38M | 5.33M | 5.31M | 6.71M | 6.42M | 3.98M | 3.98M | 3.94M | 1.49M | 1.49M | 1.49M | 1.43M | 1.28M | 1.20M | 1.20M | 1.15M | 1.14M | 1.10M | 1.02M | 1.00M | 947.04K | 945.79K | 1.00M | 1.00M | 1.00M | 891.30K | 1.00M | 1.00M | 500.00K | 666.67K | 1.00M | 800.00K | 666.67K | 722.22K |
Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors
BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr....
Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule
BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq...
Teligent, Inc. Announces Third Quarter 2020 Results
BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.
Teligent: 7 Things for Investors to Know About TLGT Stock
Shares of TLGT stock are soaring on Monday ahead of a special shareholder vote to address Teligent's Nasdaq compliance. The post Teligent: 7 Things for Investors to Know About TLGT Stock appeared first on InvestorPlace.
Why Is It Moving? Analyzing The Upward Movement in Teligent's Stock Today
Teligent (NASDAQ: TLGT) is currently up 67.3% to a price of $1.12. Monday the stock has been traded at a volume of 36.45 million, about 851.24% of its recent 30-day volume average of 4.28 million.
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Scheduled to Reconvene on December 16 , 2020 Company Urgently Encourages Stockholders to Vote
Teligent, Inc. Announces Adjournment of Special Meeting of Stockholders
Scheduled to Reconvene on November 25 , 2020 Company Urgently Encourages Stockholders to Vote
TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for potential breaches of fiduciary duty on the part...
FRIDAY DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities...
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teligent, Inc. (“Teligent” or “the Company”) (NASDAQ: TLGT) for violations of §§10(b) and 20(a) of the Securities...
Source: https://incomestatements.info
Category: Stock Reports